Such an alteration is believed to trigger a malignant transformation in rat ovarian epithelial cells, supporting DMBA use in an experimental model since a change in Tp53 is a frequent mutation in human ovarian tumors [12]. The gene discussed is TP53; the disease is ovarian neoplasm.